会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Functional Epitopes of Streptococcus Pneumoniae PsaA Antigen and Uses Thereof
    • 肺炎链球菌PsaA抗原的功能表位及其用途
    • US20080305123A1
    • 2008-12-11
    • US11992719
    • 2005-07-29
    • Edwin W. AdesJacquelyn S. SampsonSandra SteinerGeorge M. CarloneJoseph J. CabaGowriSankar Rajam
    • Edwin W. AdesJacquelyn S. SampsonSandra SteinerGeorge M. CarloneJoseph J. CabaGowriSankar Rajam
    • A61K39/09C07K14/00C12N5/00A61P31/04C07K16/12G01N33/569
    • C07K14/3156A61K39/00A61K2039/505Y10S530/825
    • Provided is a P4 peptide, which contains functional epitopes of the PsaA protein of Streptococcus pneumoniae, and related methods and compositions. A peptide that comprises the amino acid sequence defined in SEQ ID NO:1 (an example of the P4 peptide) is provided. Also provided is a peptide comprising the amino acid sequence defined as VPSLFVDSSVDDRPMKTVSQDTNIPIYAQIFTDS (SEQ ID NO:2). P4 peptide mimetics having a conformational structure identical or similar to the conformation of P4 (e.g., SEQ ID NO: 1 and SEQ ID NO:2) are provided. An antibody that specifically binds to the epitope defined by the disclosed peptides is provided. For example, the antibody can specifically bind to a peptide comprising the sequence set forth in SEQ ID NO: 1 and having the conformation defined by the peptide consisting of SEQ ID NO: 1. An antibody that specifically binds to a peptide comprising the sequence set forth in SEQ ID NO:2 and having the conformation defined by the peptide consisting of SEQ ID NO:2 is also provided. A P4-specific antibody is PsaA-specific since P4 defines an epitope specific for PsaA. A vaccine comprising the peptide of SEQ ID NO: 1 and a pharmaceutical carrier is provided. A vaccine comprising a peptide of SEQ ID NO:2 and a pharmaceutical carrier is also provided. Methods of using the peptides and antibodies of the invention are provided. Diagnostic kits comprising a P4 peptide is also provided.
    • 提供了含有肺炎链球菌PsaA蛋白的功能性表位的P4肽及其相关方法和组合物。 提供了包含SEQ ID NO:1中定义的氨基酸序列(P4肽的实例)的肽。 还提供了包含定义为VPSLFVDSSV DDRPMKTVSQDTNIPIYAQIFTDS(SEQ ID NO:2)的氨基酸序列的肽。 提供了具有与P4的构象相同或相似的构象结构的P4肽模拟物(例如,SEQ ID NO:1和SEQ ID NO:2)。 提供了特异性结合由公开的肽定义的表位的抗体。 例如,抗体可以特异性结合包含SEQ ID NO:1所示序列并具有由SEQ ID NO:1组成的肽所定义的构象的肽。特异性结合包含序列集的肽的抗体 还提供了具有由SEQ ID NO:2组成的肽定义的构象的SEQ ID NO:2中的SEQ ID NO:2。 P4特异性抗体是PsaA特异性的,因为P4定义了PsaA特异性表位。 提供了包含SEQ ID NO:1的肽和药物载体的疫苗。 还提供了包含SEQ ID NO:2的肽和药物载体的疫苗。 提供使用本发明的肽和抗体的方法。 还提供了包含P4肽的诊断试剂盒。
    • 5. 发明授权
    • Peptide vaccines against group A streptococci
    • 针对A组链球菌的肽疫苗
    • US08420107B2
    • 2013-04-16
    • US13427477
    • 2012-03-22
    • Bernard W. BeallGeorge M. CarloneJacquelyn S. SampsonEdwin W. Ades
    • Bernard W. BeallGeorge M. CarloneJacquelyn S. SampsonEdwin W. Ades
    • A61K39/09C07K14/315
    • A61K39/092A61K39/00C07K14/001C07K14/315C07K2319/00
    • This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines.
    • 本发明在一个方面涉及合成免疫反应肽。 这些肽的长度约为20-25个氨基酸,它们是最流行的美国(A)链球菌(GAS)血清型的M蛋白的N末端的部分。 至少一些合成肽可被M型特异性抗体识别,并且能够引发功能性调理抗体和/或抗附着抗体而不引发组织交叉反应性抗体。 另一方面,本发明涉及包含这些合成血清型特异性肽(包括多肽和蛋白质)的组合物或疫苗。 本发明还可以是响应于肽,组合物或疫苗引起的分离的抗体。 本发明还涉及使用肽,组合物或抗体的试剂盒。 在另外的方面,本发明还涉及使用肽,组合物,疫苗或抗体的方法和用于定制疫苗的方法。
    • 7. 发明授权
    • Peptide vaccines against Group A streptococci
    • 针对A组链球菌的肽疫苗
    • US07883710B2
    • 2011-02-08
    • US12144461
    • 2008-06-23
    • Bernard W. BeallGeorge M. CarloneJacquelyn S. SampsonEdwin W. Ades
    • Bernard W. BeallGeorge M. CarloneJacquelyn S. SampsonEdwin W. Ades
    • A61K39/09C07H21/04C07K4/04C12P21/06
    • A61K39/092A61K39/00C07K14/001C07K14/315C07K2319/00
    • This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines.
    • 本发明在一个方面涉及合成免疫反应肽。 这些肽的长度约为20-25个氨基酸,它们是最流行的美国(A)链球菌(GAS)血清型的M蛋白的N末端的部分。 至少一些合成肽可被M型特异性抗体识别,并且能够引发功能性调理抗体和/或抗附着抗体而不引发组织交叉反应性抗体。 另一方面,本发明涉及包含这些合成血清型特异性肽(包括多肽和蛋白质)的组合物或疫苗。 本发明还可以是响应于肽,组合物或疫苗引起的分离的抗体。 本发明还涉及使用肽,组合物或抗体的试剂盒。 在另外的方面,本发明还涉及使用肽,组合物,疫苗或抗体的方法和用于定制疫苗的方法。
    • 8. 发明申请
    • PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI
    • 肽类疫苗对A组STREPTOCOCCI
    • US20110110969A1
    • 2011-05-12
    • US12973247
    • 2010-12-20
    • Bernard W. BeallGeorge M. CarloneJacquelyn S. SampsonEdwin W. Ades
    • Bernard W. BeallGeorge M. CarloneJacquelyn S. SampsonEdwin W. Ades
    • A61K39/09C07K14/315A61P31/04A61K39/116
    • A61K39/092A61K39/00C07K14/001C07K14/315C07K2319/00
    • This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines.
    • 本发明在一个方面涉及合成免疫反应肽。 这些肽的长度约为20-25个氨基酸,它们是最流行的美国(A)链球菌(GAS)血清型的M蛋白的N末端的部分。 至少一些合成肽可被M型特异性抗体识别,并且能够引发功能性调理抗体和/或抗附着抗体而不引发组织交叉反应性抗体。 另一方面,本发明涉及包含这些合成血清型特异性肽(包括多肽和蛋白质)的组合物或疫苗。 本发明还可以是响应于肽,组合物或疫苗引起的分离的抗体。 本发明还涉及使用肽,组合物或抗体的试剂盒。 在另外的方面,本发明还涉及使用肽,组合物,疫苗或抗体的方法和用于定制疫苗的方法。
    • 9. 发明授权
    • Multiple antigenic peptides immunogenic against Streptococcus pneumonia
    • 针对肺炎链球菌免疫原性的多种抗原肽
    • US07501132B2
    • 2009-03-10
    • US11145814
    • 2005-06-06
    • Edwin W. AdesScott E. JohnsonDanny L. JueJacquelyn S. SampsonGeorge M. Carlone
    • Edwin W. AdesScott E. JohnsonDanny L. JueJacquelyn S. SampsonGeorge M. Carlone
    • A61K39/09A61K39/02A61K39/38A61K39/385A61K38/00A01N37/18
    • C07K7/08A61K38/00A61K39/00C07K14/3156Y10S530/806Y10S530/825
    • The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention further provides monoclonal antibodies which selectively bind PsaA. In addition, peptides are provided that immunospecifically bind to the monoclonal antibodies of the invention, and that are immunogenic against Streptococcus pneumoniae infection. Additionally, multiple antigenic peptides that provide protection against S. pneumoniae challenge are provided. These multiple antigen peptides comprise the peptides that immunospecifically bind to the monoclonal antibodies. Also provided are vaccines comprising such immunogenic peptides, and methods of conferring protective immunity against Streptococcus pneumoniae infection by administering therapeutic composition comprising the immunogenic peptides of the invention. Also provided are methods of detecting the presence of Streptococcus pneumoniae in a sample using antibodies or antigens and methods of preventing and treating Streptococcus pneumoniae infection in a subject. In addition, a method of identifying the sequence of a peptide potentially capable of eliciting protective immunity against a pathogenic microorganism is provided.
    • 本发明提供编码来自肺炎链球菌的37-kDa肺炎球菌表面粘附A蛋白(PsaA)的核酸。 还提供了分离的核酸,其包含37-kDa蛋白质的至少10个核苷酸的独特片段。 本发明还提供由编码37-kDa蛋白质的核酸编码的纯化多肽和包含37-kDa蛋白质至少10个核苷酸的独特片段的核酸。 本发明还提供选择性结合PsaA的单克隆抗体。 此外,提供了免疫特异性结合本发明的单克隆抗体并且对肺炎链球菌感染具有免疫原性的肽。 另外,提供了提供针对肺炎链球菌攻击的保护的多种抗原肽。 这些多重抗原肽包含免疫特异性结合单克隆抗体的肽。 还提供了包含这种免疫原性肽的疫苗,以及通过施用包含本发明的免疫原性肽的治疗组合物来赋予对肺炎链球菌感染的保护性免疫的方法。 还提供了使用抗体或抗原检测样品中肺炎链球菌存在的方法以及在受试者中预防和治疗肺炎链球菌感染的方法。 此外,提供了鉴定潜在地能够引发对病原微生物的保护性免疫的肽的序列的方法。
    • 10. 发明申请
    • PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI
    • 肽类疫苗对A组STREPTOCOCCI
    • US20080279880A1
    • 2008-11-13
    • US12144461
    • 2008-06-23
    • Bernard W. BeallGeorge M. CarloneJacquelyn S. SampsonEdwin W. Ades
    • Bernard W. BeallGeorge M. CarloneJacquelyn S. SampsonEdwin W. Ades
    • A61K39/02A61K38/16A61K39/095A61K39/10A61K38/10
    • A61K39/092A61K39/00C07K14/001C07K14/315C07K2319/00
    • This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines.
    • 本发明在一个方面涉及合成免疫反应肽。 这些肽的长度约为20-25个氨基酸,它们是最流行的美国(A)链球菌(GAS)血清型的M蛋白的N末端的部分。 至少一些合成肽可被M型特异性抗体识别,并且能够引发功能性调理抗体和/或抗附着抗体而不引发组织交叉反应性抗体。 另一方面,本发明涉及包含这些合成血清型特异性肽(包括多肽和蛋白质)的组合物或疫苗。 本发明还可以是响应于肽,组合物或疫苗引起的分离的抗体。 本发明还涉及使用肽,组合物或抗体的试剂盒。 在另外的方面,本发明还涉及使用肽,组合物,疫苗或抗体的方法和用于定制疫苗的方法。